There is one clinical trial.
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept
administered to hospitalized COVID-19 participants with respiratory compromise.
Primary Outcomes
Measure: Proportion of participants with composite end point of mechanical ventilation or death prior to or on Day 28 Time: Up to 28 days
Secondary Outcomes
Measure: Change from baseline in the Ordinal 8-point Outcome Scale on Day 28 Time: Day 28
Measure: All-cause mortality on Day 28 Time: Day 28
Measure: Proportion of participants alive and free of respiratory failure on Day 28 Time: Day 28
Measure: Proportion of participants returned to room air by Day 28 Time: Up to 28 days
Measure: Proportion of participants alive and discharged home by Day 28 Time: Up to 28 days
Measure: Proportion of participants with Serious Adverse Events (SAEs) Time: Up to 60 days
Measure: Proportion of participants with serious infections Time: Up to 60 days